Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah Last updated November 2025